SCHEMBL6798709

SCHEMBL6798709

CCOC(=O)c1cc2c(C)c(O)ccc2n1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
KDM4E B2RXH2 3/20 0.46
LMNA P02545 2/20 0.46
GAA P10253 2/20 0.46
HPGD P15428 1/20 0.46
ESR1 P03372 1/20 0.45
CA12 O43570 3/20 0.45
CA1 P00915 3/20 0.45
CA2 P00918 3/20 0.45
CA7 P43166 3/20 0.45
CA9 Q16790 3/20 0.45
CA14 Q9ULX7 3/20 0.45
HSD17B10 Q99714 1/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.43
ALOX5 P09917 4/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL13684574 0.83 MAPT (0.52) ALDH1A1SMN1; SMN2KDM4ELMNAGAA
SCHEMBL5005300 0.83 CA12 (0.53) ALDH1A1SMN1; SMN2KDM4ELMNAGAA
SCHEMBL7246268 0.79 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2KDM4ELMNAGAA
SCHEMBL6803759 0.78 ESR1 (0.49) ALDH1A1SMN1; SMN2KDM4ELMNAGAA
SCHEMBL19332145 0.77 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2KDM4ELMNAGAA
SCHEMBL19331938 0.77 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2KDM4ELMNAGAA
SCHEMBL6797552 0.76 KDM4E (0.49) ALDH1A1SMN1; SMN2KDM4ELMNAGAA
SCHEMBL7873379 0.76 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2KDM4ELMNAGAA
SCHEMBL22042092 0.76 KDM4E (0.50) ALDH1A1SMN1; SMN2KDM4ELMNAGAA
SCHEMBL27378256 0.76 ALOX5 (0.49) ALDH1A1SMN1; SMN2KDM4ELMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6734205-B2 SODIUM CHANNEL MODERATORS; CARDIOVASCULAR DISORDERS; ANTIDIABETIC AGENTS SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2004-05-11 US disclosed
US-20030018056-A1 Substituted guanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2003-01-23 US disclosed
EP-1238971-A1 SUBSTITUTED GUANIDINE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018056-A1 Substituted guanidine derivatives SLC28A1, SLC7A1, ABCB11 ALDH1A1 1321/4885SMN1; SMN2 1381/4885KDM4E 1068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.